News and Trends 8 Sep 2022 First patient dosed in China trial with drug to treat non-Hodgkin lymphoma The dosing of the first patient at a clinical trial in China for patients with relapsed/refractory non-Hodgkin lymphoma (NHL) was announced yesterday (September 7). CASI Pharmaceuticals and BioInvent International AB are running the phase 1, dose-escalation and expansion study of BI-1206. The treatment is a fully human monoclonal antibody (mAb) that targets FcyRIIB, in combination […] September 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Startup Scout 8 Sep 2022 Stratosvir is overcoming the viral immunotherapy delivery bottleneck The U.K. startup Stratosvir is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. Cancer immunotherapies have made great strides in the last decade, with some of the most important advances including CAR-T cell therapy and checkpoint inhibitors. One oncology field […] September 8, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Cytiva launches BioChallenge in Southeast Asia to support biotech startups Cytiva has launched its BioChallenge competition in Southeast Asia to help small to medium sized biotech companies in the fields of cell engineering, process development, as well as isolation and purification. Winners of the BioChallenge will be awarded up to SG$200,000 ($142,000) in FastTrak services so that they can scale up efficiently, mitigate risks, and […] September 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Integral Molecular joins FDA’s ISTAND program Integral Molecular has been accepted into the U.S. Food & Drug Administration (FDA)’s ISTAND (Innovative Science and Technology Approaches for New Drugs) pilot program. The program supports, and was created to expand, the drug development tool types listed in the 21st Century Cures legislation. A major goal of the pilot program is to qualify these […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Onego Bio secures extra funding for egg white production technology Onego Bio is a biotech spin-off from VTT Technical Research Centre of Finland. The company uses a commercially proven Trichoderma technology to solve environmental problems associated with eggs, one of the world’s most used animal proteins. Onego Bio said its sustainable and cost-effective precision fermentation method produces ovalbumin, the most abundant egg white protein, and […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Lutris Pharma radiation trial brings positive results for breast cancer patients Top line results from a clinical trial treating breast cancer patients with radiation dermatitis (RD) have been positive. Lutris Pharma, based in Israel, is a biopharma company focused on improving cancer therapies. It announced its results from the open label part 1 and double blinded part 2 of it phase 1/2 trial yesterday (September 7). […] September 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 From tobacco to table – cell-cultured meat venture receives $10M funding to scale-up production Cell cultured meat could now be produced on a broader scale thanks to funding of $10 million invested in the Israeli start-up BioBetter Ltd. Food-tech BioBetter Ltd., received the significant injection of capital in its series A round of funding which was led by Jerusalem Venture Partners (JVP) with additional investment from Milk and Honey […] September 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Report looks at the future of clinical trials Medidata, a Dassault Systèmes company, has published a report, ‘European Industry Research Report: The Future of Clinical Trials’. The report draws on new independent research that includes insights from 400 clinical trial executives across the U.K., France, Germany and Switzerland. They were surveyed to gain a deeper understanding of how clinical trials have changed over […] September 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Omnio receives funding for wound treatment Swedish company Omnio AB has shown plasminogen is a pro-inflammatory regulator of inflammation that can be used to treat chronic wounds with dysfunctional inflammation. The company, a spin off from Umeå University, said the drug could mean a global treatment revolution for wounds that never heal. Non-healing chronic wounds are a major global health problem […] September 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 OncoBone signs deals with three partners to work on bone metastases OncoBone Ventures has signed cooperation framework agreements with three partners. The company is a U.K. start up biotech looking to develop novel therapies for cancer patients with currently incurable bone metastases. The partners are: Okayama University in Japan, the University of Bradford in the U.K., and The Development Center for Biotechnology in Taiwan. The agreements […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […] September 8, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Cultivated Biosciences raises $1.5M to take fats to the next frontier Cultivated Biosciences, an ingredient startup biotech company founded by Swiss entrepreneurs Tomas Turner and Dimitri Zogg, has just raised a $1.5M pre-seed round. The funding will enable the growing team to further optimize its production processes, research food applications and start product development of its creamy ingredient for dairy alternatives from non-GMO yeast with their […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email